Driving cessation following an Acquired Brain Injury (ABI) presents significant challenges, often inhibiting community participation and degrading quality of life. Recognizing this dilemma, researchers have developed a structured support program targeting individuals who can no longer drive. A non-randomized trial protocol has been designed to evaluate this initiative in Japan, aimed at enhancing community participation through the Community Life Support Program for Individuals with Acquired Brain Injury after Driving Cessation (CLASP-AID).
The trial, set in a convalescent rehabilitation hospital, uses a ward-level cluster allocation approach. Participants with documented driving cessation due to ABI are assigned to either the intervention group, which engages in the CLASP-AID program, or the control group that receives usual care. CLASP-AID comprises educational sessions that involve both the individuals and, when necessary, their family members, offering insights into alternative transportation modes and training on mobility devices.
The primary outcome of interest is assessed using the Canadian Occupational Performance Measure (COPM), specifically evaluating post-intervention scores after the program's completion. Secondary outcome measures will include aspects such as readiness for mobility transition, health-related quality of life, and levels of depressive symptoms, all evaluated via various validated tools at both baseline and post-intervention.
The target population for this trial includes individuals aged 55 years and older who are frequenting either inpatient or outpatient services at the rehabilitation center. Participants must have undergone a driving assessment affirming their inability to resume driving and must provide informed consent, demonstrating adequate cognitive ability to comprehend the study requirements. Exclusion criteria encompass conditions disallowing driving, such as certain psychiatric disorders, marked cognitive impairments, or communication difficulties, ensuring a homogenous study cohort capable of engaging with the program.
As of August 16, 2026, recruitment concluded with 27 participants enrolled—10 in the control group and 17 in the intervention group—following successful identification and screening processes led by occupational therapists in the hospital setting. The overall aim is to facilitate a deeper understanding of how structured community support can address not only mobility challenges but also the emotional and social ramifications of driving cessation.
This research is classified as a pilot study with a modest target sample size of approximately 30 participants, allowing for attrition and incomplete follow-ups. With recruitment completed by September 30, 2026, and follow-up assessments scheduled until March 31, 2027, the study seeks to document efficacy through observed changes in the primary outcome and gather data to inform larger, definitive trials. All data collected will begin on paper forms before secure digital entry into a protected database for analysis.
Ethical oversight has been prioritized; the study secured approval from the Institutional Ethics Committee of the Nakaizu Rehabilitation Center prior to participant engagement. Consent protocols were implemented to ensure participants understood the study’s nature and their rights within it. Written consent was obtained from each participant post-explanation, creating a transparent framework for ethical standards.
The comprehensive consent process includes oral explanations and documentation of the participants’ willingness to engage. Should any new information arise potentially altering a participant's decision mid-study, they will be informed, reflecting the research’s commitment to ethical integrity.
The trial is structured as a single-center, non-randomized controlled trial with ward allocation defining study groups. With patients assigned based on their ward placement, the design minimizes the risk of contamination between groups while recognizing the inherent limitations of non-randomized designs. Conducted within a post-acute rehabilitation setting, the study will draw on real-world patient experiences to provide insight into the program’s impact on quality of life for individuals with ABI following driving cessation.
The CLASP-AID program will be implemented alongside usual care within the therapeutic framework of the rehabilitation hospital environment, promoting individual engagement with community resources and mobility alternatives as vital components of recovery. Outcomes will inform future developments of structured interventions aimed at supporting individuals navigating the complexities of life post-driving cessation. Among the critical next steps, the study's findings are anticipated to lay groundwork for comprehensive evidence-based strategies that bolster community participation and mobility among impacted populations.